3NQ.F NanoCarrier Co. Ltd
- Market cap
- EUR 32.3M
- P/E
- -
- P/B
- 1.68x
- ROE
- -34.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is 3NQ.F undervalued?
Graham numberThe Graham number of NanoCarrier Co. Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NanoCarrier Co. Ltd fundamental analysis
No fundamental analysis for NanoCarrier Co. Ltd yet.
NanoCarrier Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NanoCarrier Co. Ltd
Nano Holdings, Inc. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan. The company's pipeline products include RUNX1 (mRNA) for the treatment knee osteoarthritis and reduces pain. Its product pipeline also comprises TUG1 (ASO) for glioblastoma multiforme. In addition, it offers cosmetic raw material. The company was formerly known as NANO MRNA Co.,Ltd. and changed its name to Nano Holdings, Inc. in December 2025. Nano …
Full company profileNanoCarrier Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NanoCarrier Co. Ltd annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 219M | 259M | 497M | 553M | 313M | 264M | 202M | 136M | 109M | 174M | 143M |
| Gross Profit | 158M | 191M | 417M | 475M | 275M | 223M | 160M | 111M | 78.2M | 153M | 132M |
| Operating Income | -2.71B | -5.35B | -1.80B | -1.11B | -1.30B | -2.06B | -1.25B | -864M | -755M | -966M | -1.10B |
| EBITDA | - | -5.33B | -1.79B | -1.10B | -1.30B | -2.06B | -1.25B | -863M | -833M | -917M | -1.07B |
| Net Income | -2.68B | -5.42B | -1.81B | -2.01B | -2.84B | -1.88B | -1.31B | -780M | -835M | -944M | -1.13B |
| EPS | -62 | -125 | -37 | -30 | -41 | -27 | -19 | -11 | -12 | -12 | -13 |
| Balance Sheet | |||||||||||
| Total Assets | 12.9B | 7.63B | 8.57B | 8.94B | 7.82B | 7.14B | 5.78B | 5.07B | 4.00B | 5.91B | 5.24B |
| Total Liabilities | 2.87B | 2.97B | 2.69B | 176M | 321M | 1.57B | 1.53B | 1.65B | 1.26B | 2.34B | 1.92B |
| Shareholders' Equity | 10.1B | 4.66B | 5.88B | 8.77B | 7.50B | 5.57B | 4.25B | 3.42B | 2.74B | 3.57B | 3.31B |
| Cash & Short-term Investments | 9.40B | 3.69B | 4.57B | 4.47B | 3.89B | 3.55B | 2.81B | 2.08B | 1.71B | 4.91B | 4.22B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.53B | -4.93B | -2.04B | -1.14B | -1.25B | -1.75B | -1.09B | -585M | -402M | -817M | - |
| Capital Expenditure | 177M | 61.0M | 6.00M | 5.00M | 5.00M | 5.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | -4.99B | -2.04B | -1.14B | -1.25B | -1.76B | -1.09B | -585M | -402M | -817M | - |
| Ratios | |||||||||||
| ROE | -26.6% | -116.2% | -30.8% | -22.9% | -37.8% | -33.8% | -30.8% | -22.8% | -30.5% | -26.5% | -34.0% |
| ROA | -20.7% | -71.0% | -21.1% | -22.5% | -36.3% | -26.4% | -22.7% | -15.4% | -20.9% | -16.0% | -21.5% |
| Net Profit Margin | -1,223.6% | -2,090.6% | -364.1% | -363.4% | -905.2% | -712.7% | -648.4% | -575.6% | -769.8% | -540.9% | -788.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NanoCarrier Co. Ltd dividends
NanoCarrier Co. Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 100:1 on Mar 27, 2014.
Who owns NanoCarrier Co. Ltd
- Insiders 7.06%
- Institutions 0.14%
- Public & others 92.80%
- Shares outstanding 83.7M
- Free float 78.6M
NanoCarrier Co. Ltd company profile
- Company name
- NanoCarrier Co. Ltd
- Ticker
- 3NQ.F
- ISIN
- JP3651120002
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 23
- Fiscal year end
- March
- Address
- 2-5-1 Atago, Minato, Japan
- Phone
- 81 3 6432 0020
- Website
- nanomrna.co.jp
About NanoCarrier Co. Ltd
Nano Holdings, Inc. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan. The company's pipeline products include RUNX1 (mRNA) for the treatment knee osteoarthritis and reduces pain. Its product pipeline also comprises TUG1 (ASO) for glioblastoma multiforme. In addition, it offers cosmetic raw material. The company was formerly known as NANO MRNA Co.,Ltd. and changed its name to Nano Holdings, Inc. in December 2025. Nano Holdings, Inc. was incorporated in 1996 and is headquartered in Minato, Japan.
NanoCarrier Co. Ltd management
5- Mr. Takashi MatsuoCFO, Chief Administrative Officer, Chief Compliance Office & Director · born 1961
- Mr. Satoru IinoDirector & Chief Investment Officer · born 1965
- Dr. Shiro Akinaga Ph.D.CTO & Director · born 1956
- Dr. Ichiro Nakatomi Ph.D.Chief Networking Officer & Director · born 1950
- Nobuhiro TodokoroChief Growth Officer & Director · born 1965